ZEVRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 USD | -0.63% |
|
-1.87% | -27.79% |
| May. 13 | Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call | |
| May. 08 | Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12.6 | 48.32 | 307.6 | 158.4 | 271.7 | 198 | - | - |
| Enterprise Value (EV) 1 | 12.6 | 48.32 | 307.6 | 55.53 | 271.7 | 198 | 198 | 198 |
| P/E ratio | -0.46 x | -3.49 x | -4.13 x | -3.83 x | -5.04 x | -3.16 x | -11.6 x | 7.72 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.98 x | 3.64 x | 10.7 x | 15.1 x | 9.9 x | 6.99 x | 2.07 x | 1.23 x |
| EV / Revenue | 0.98 x | 3.64 x | 10.7 x | 15.1 x | 9.9 x | 6.99 x | 2.07 x | 1.23 x |
| EV / EBITDA | - | - | - | -3,810,717 x | - | - | - | - |
| EV / FCF | - | - | - | -8.42 x | - | -4.74 x | -20.8 x | 6.97 x |
| FCF Yield | - | - | - | -11.9% | - | -21.1% | -4.8% | 14.3% |
| Price to Book | - | - | - | 1.84 x | - | - | - | - |
| Nbr of stocks (in thousands) | 2,076 | 4,315 | 35,319 | 34,505 | 41,485 | 41,853 | - | - |
| Reference price 2 | 6.069 | 11.20 | 8.710 | 4.590 | 6.550 | 4.730 | 4.730 | 4.730 |
| Announcement Date | 2/28/20 | 3/11/21 | 3/30/22 | 3/7/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.84 | 13.29 | 28.65 | 10.46 | 27.46 | 28.34 | 95.58 | 161 |
| EBITDA | - | - | - | -41.56 | - | - | - | - |
| EBIT 1 | -20.34 | -5.609 | 7.729 | -42.5 | -49.6 | -66.3 | -11.89 | 38.39 |
| Operating Margin | -158.4% | -42.21% | 26.98% | -406.44% | -180.63% | -233.94% | -12.44% | 23.84% |
| Earnings before Tax (EBT) 1 | -24.52 | -12.79 | -8.521 | -42.33 | -46.05 | -68.39 | -16.7 | 35.03 |
| Net income 1 | -24.54 | -12.76 | -62.9 | -41.54 | -46.05 | -68.34 | -16.7 | 34.08 |
| Net margin | -191.17% | -96.03% | -219.54% | -397.24% | -167.69% | -241.15% | -17.47% | 21.16% |
| EPS 2 | -13.28 | -3.210 | -2.110 | -1.200 | -1.300 | -1.497 | -0.4080 | 0.6125 |
| Free Cash Flow 1 | - | - | - | -18.81 | - | -41.8 | -9.5 | 28.4 |
| FCF margin | - | - | - | -179.86% | - | -147.5% | -9.94% | 17.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 83.34% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 3/11/21 | 3/30/22 | 3/7/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.582 | 3.965 | 1.3 | 2.874 | 2.319 | 2.879 | 8.47 | 2.895 | 13.22 | 3.425 | 4.519 | 5.562 | 15 | 13.93 | 17.32 |
| EBITDA | - | - | - | -6.228 | -8.953 | -12.84 | -6.567 | -15.3 | - | - | - | - | - | - | - |
| EBIT 1 | -2.842 | -1.859 | -24.77 | -6.626 | -9.253 | -12.92 | -6.645 | -15.36 | -14.67 | -20.49 | -17.95 | -17.32 | -10.99 | - | - |
| Operating Margin | -110.07% | -46.89% | -1,905.15% | -230.55% | -399.01% | -448.91% | -78.45% | -530.71% | -111% | -598.13% | -397.28% | -311.45% | -73.24% | - | - |
| Earnings before Tax (EBT) 1 | -2.669 | -1.868 | -24.76 | -6.649 | -9.055 | -11.87 | -5.158 | -13.87 | -15.15 | -16.69 | -19.15 | -18.82 | -12.49 | - | - |
| Net income 1 | -2.703 | -1.864 | -24.04 | -6.616 | -9.021 | -11.77 | -5.084 | -14.04 | -15.15 | -16.62 | -19.15 | -18.82 | -12.49 | - | - |
| Net margin | -104.69% | -47.01% | -1,849.38% | -230.2% | -389% | -408.72% | -60.02% | -485.15% | -114.65% | -485.31% | -423.77% | -338.39% | -83.25% | - | - |
| EPS 2 | -0.0800 | -0.0500 | -0.7000 | -0.1900 | -0.2600 | -0.3400 | -0.1500 | -0.4000 | -0.4000 | -0.4000 | -0.4267 | -0.4200 | -0.2517 | -0.2500 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/12/22 | 8/11/22 | 11/9/22 | 3/7/23 | 5/15/23 | 8/14/23 | 11/7/23 | 3/28/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | 103 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -18.8 | - | -41.8 | -9.5 | 28.4 |
| ROE (net income / shareholders' equity) | - | - | - | -39% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | 2.490 | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | -0.5400 | - | -0.6900 | 0.1100 | 0.7600 |
| Capex 1 | - | - | - | 0.09 | - | 1.1 | 1.78 | 2.55 |
| Capex / Sales | - | - | - | 0.89% | - | 3.88% | 1.87% | 1.58% |
| Announcement Date | 2/28/20 | 3/11/21 | 3/30/22 | 3/7/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.73
USD
Average target price
19
USD
Spread / Average Target
+301.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.79% | 198M | |
| +16.03% | 79.03B | |
| +10.23% | 8.96B | |
| -10.76% | 5.19B | |
| +51.58% | 4.77B | |
| +12.50% | 4.26B | |
| -20.70% | 2.37B | |
| +12.83% | 2.3B | |
| -29.65% | 2.21B | |
| +19.51% | 2.17B |
- Stock Market
- Equities
- ZVRA Stock
- Financials Zevra Therapeutics, Inc.